Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2014; 20(41): 15110-15118
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15110
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15110
S-1 in the treatment of pancreatic cancer
Kentaro Sudo, Kazuyoshi Nakamura, Taketo Yamaguchi, Department of Gastroenterology, Chiba Cancer Center, Chiba 260-8717, Japan
Author contributions: Sudo K performed the literature search, performed data analysis, and wrote the manuscript; Nakamura K and Yamaguchi T performed data analysis and edited the manuscript.
Correspondence to: Kentaro Sudo, MD, PhD, Department of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan. kentarosudo9@yahoo.co.jp
Telephone: +81-43-2645431 Fax: +81-43-2628680
Received: October 28, 2013
Revised: April 7, 2014
Accepted: April 30, 2014
Published online: November 7, 2014
Processing time: 377 Days and 19.2 Hours
Revised: April 7, 2014
Accepted: April 30, 2014
Published online: November 7, 2014
Processing time: 377 Days and 19.2 Hours
Core Tip
Core tip: This review article focuses on clinical trials of S-1-based chemotherapy for advanced pancreatic cancer. Recently, S-1 has been demonstrated to be non-inferior to gemcitabine in overall survival for metastatic or locally advanced pancreatic cancer in a large-scale phase III study (GEST study). Furthermore, S-1 has been shown to be superior to adjuvant chemotherapy with gemcitabine in overall survival in patients with resected pancreatic cancer in another phase III study (JASPAC-01 study). In addition to gemcitabine, S-1 is now considered one of the key drugs in Japan.